Omnicell to Acquire Pharmaceutical Strategy Group’s 340B Link Business
August 12, 2020
Plano, Texas – Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has entered into a definitive agreement with Pharmaceutical Strategies Group (PSG) to acquire its 340B Link business. You’ll find all the details at omnicell.com.
PSG is the leading pharmacy intelligence and technology company solving one of healthcare’s biggest challenges – rising drug costs. We provide innovative drug management solutions to over 300 clients who rely on our team of trusted advisors to improve their financial performance.